Biosensor market seen reaching $65.81B by 2035

The global biosensor market is projected to grow from $27.8 billion in 2025 to $65.81 billion by 2035, according to Market Research Future. Growth is being driven by chronic disease management, point-of-care testing, wearables and AI-enabled monitoring as healthcare shifts away from centralized labs.

Why it matters: - Biosensors are moving deeper into everyday care as hospitals, pharmacies and homes adopt faster testing and continuous monitoring. - The market’s growth reflects rising demand for tools that can track chronic disease, support decentralized diagnostics and feed real-time data into digital health systems. - The shift could expand access to testing while reducing dependence on centralized laboratory workflows.

What happened: - Market Research Future projects the global biosensor market will rise from $27.80 billion in 2025 to $65.81 billion by 2035. - The forecast implies a 9.00% CAGR during 2026 to 2035. - The market is also expected to reach $30.30 billion in 2026. - The report was released Sept. 3, 2026. - Request a free sample.

The details: - The market’s growth is tied to three main forces: rising chronic disease prevalence, sensing technology advances and wider use of digital health tools. - The World Health Organization estimates 1.27 billion people will live with diabetes by 2050. - WHO data show diabetes, cardiovascular disease and chronic kidney disease affect more than 1.5 billion people globally. - The IDF Diabetes Atlas projects global diabetes spending will exceed $1.05 trillion annually by 2030. - Abbott Laboratories remains a major player through FreeStyle Libre continuous glucose monitoring and the i-STAT point-of-care platform. - F. Hoffmann-La Roche continues to generate revenue through Accu-Chek and the cobas analyzer ecosystem. - DexCom is advancing continuous glucose monitoring with the G7 and Stelo over-the-counter sensor. - The report says AI-powered miniaturized devices and multi-analyte wearable platforms are improving detection speed, accuracy and convenience. - Cloud analytics, mobile apps and telehealth are also being used to improve real-time monitoring and clinical decision-making. - Read the full report.

Between the lines: - The market is shifting from episodic testing toward continuous telemetry, which could change how chronic conditions are managed outside hospitals. - Wearable and embedded biosensors are expected to grow faster than traditional benchtop formats, suggesting consumers and providers want more portable and less invasive tools. - The report’s revenue outlook also points to a broader move toward software-connected diagnostics, not just hardware sales. - In the U.S., reimbursement expansion for rapid cardiac troponin and HbA1c testing added about 14,000 eligible testing sites in 2024, reinforcing the move to decentralized care. - The FDA’s De Novo and Breakthrough Device programs accelerated novel sensing approvals, with 18 biosensor-related clearances in 2024.

What's next: - Wearable and embedded biosensors are forecast to post a 10.70% CAGR from 2026 to 2035. - Optical biosensors are projected to grow at a 10.90% CAGR through 2035. - Home healthcare diagnostics are expected to be the fastest-growing end-user channel, with an 11.50% CAGR over the study period. - Asia-Pacific is expected to be the fastest-growing region at a 9.80% CAGR through 2035. - The report points to new opportunities in low-cost platforms for emerging markets, multi-analyte wearables, data-as-a-service models and sustainable manufacturing.

The bottom line: - Biosensors are evolving from a niche diagnostic tool into a core layer of chronic care, remote monitoring and decentralized testing.